Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.58 USD | +0.70% | -35.45% | -16.73% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.73% | 245M | |
+11.07% | 225B | |
+10.89% | 186B | |
+13.08% | 135B | |
+25.96% | 107B | |
+0.91% | 63.56B | |
+6.74% | 51.32B | |
+12.22% | 51.04B | |
+8.02% | 43.3B | |
+4.76% | 36.99B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Wells Fargo Adjusts NeuroPace's Price Target to $9 from $11, Keeps Equalweight Rating